fluticasone furoate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4554	397864-44-7

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: fluticasone furoate avamys veramyst	Fluticasone furoate is a synthetic trifluorinated corticosteroid with anti‑inflammatory activity. Fluticasone furoate has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor. The precise mechanism of corticosteroid action on asthma is not known. Inflammation is an important component in the pathogenesis of asthma. Corticosteroids have been shown to have a wide range of actions on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, cytokines) involved in inflammation. These anti-inflammatory actions of corticosteroids contribute to their efficacy in asthma. Molecular weight: 538.58 Formula: C27H29F3O6S CLOGP: 4.26 LIPINSKI: 1 HAC: 6 HDO: 1 TPSA: 93.81 ALOGS: -4.09 ROTB: 6 Status: ONP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

fluticasone furoate
avamys
veramyst

Fluticasone furoate is a synthetic trifluorinated corticosteroid with anti‑inflammatory activity. Fluticasone furoate has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor. The precise mechanism of corticosteroid action on asthma is not known. Inflammation is an important component in the pathogenesis of asthma. Corticosteroids have been shown to have a wide range of actions on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, cytokines) involved in inflammation. These anti-inflammatory actions of corticosteroids contribute to their efficacy in asthma.

Molecular weight: 538.58
Formula: C27H29F3O6S
CLOGP: 4.26
LIPINSKI: 1
HAC: 6
HDO: 1
TPSA: 93.81
ALOGS: -4.09
ROTB: 6

Status: ONP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.20	mg	N
0.11	mg	N
0.60	mg	Inhal.aerosol
0.60	mg	Inhal.powder
1.50	mg	Inhal.solution

ADMET properties:

Property	Value	Reference
Vd (Volume of distribution)	4.95 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	13.40 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	10.60 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
April 27, 2007	FDA	GLAXOSMITHKLINE
April 22, 2009	PMDA	GlaxoSmithKline K.K.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Macular degeneration	675.23	19.55	232	14003	18676	56259156
Asthma	636.98	19.55	380	13855	112390	56165442
Wheezing	384.64	19.55	238	13997	74788	56203044
Obstructive airways disorder	364.34	19.55	144	14091	17138	56260694
Full blood count abnormal	233.54	19.55	120	14115	26342	56251490
Nasal congestion	206.21	19.55	145	14090	56225	56221607
Therapeutic product effect incomplete	158.66	19.55	163	14072	105868	56171964
Dyspnoea	143.82	19.55	399	13836	592178	55685654
Sleep disorder due to a general medical condition	125.21	19.55	56	14179	9034	56268798
Gastrooesophageal reflux disease	124.49	19.55	128	14107	83129	56194703
Bronchial haemorrhage	120.35	19.55	28	14207	529	56277303
Bronchial neoplasm	119.75	19.55	27	14208	441	56277391
Blepharospasm	110.70	19.55	39	14196	3359	56274473
Cough	109.90	19.55	218	14017	259743	56018089
Throat clearing	109.71	19.55	32	14203	1498	56276334
Nasal turbinate hypertrophy	108.45	19.55	27	14208	686	56277146
Chronic sinusitis	107.11	19.55	49	14186	8329	56269503
Chest discomfort	104.79	19.55	127	14108	98730	56179102
Bronchiectasis	104.13	19.55	53	14182	11381	56266451
Blood immunoglobulin E increased	103.65	19.55	36	14199	2973	56274859
Endometrial ablation	102.06	19.55	27	14208	878	56276954
Productive cough	101.79	19.55	96	14139	56136	56221696
Bronchial disorder	99.42	19.55	28	14207	1155	56276677
Malignant mediastinal neoplasm	87.91	19.55	24	14211	881	56276951
Rhonchi	83.72	19.55	29	14206	2375	56275457
Taste disorder	82.60	19.55	43	14192	9672	56268160
Nasal polyps	82.25	19.55	31	14204	3234	56274598
Dust allergy	82.19	19.55	21	14214	594	56277238
Sputum discoloured	79.83	19.55	48	14187	14244	56263588
Hyper IgE syndrome	78.96	19.55	19	14216	417	56277415
Respiratory tract inflammation	73.54	19.55	19	14216	562	56277270
Total lung capacity increased	72.94	19.55	21	14214	938	56276894
Dyspnoea exertional	72.65	19.55	79	14156	54610	56223222
Rhinorrhoea	71.63	19.55	80	14155	56957	56220875
Asthma-chronic obstructive pulmonary disease overlap syndrome	69.48	19.55	19	14216	702	56277130
Rhinitis	68.82	19.55	37	14198	8879	56268953
Secretion discharge	68.34	19.55	39	14196	10507	56267325
Restrictive pulmonary disease	67.35	19.55	22	14213	1504	56276328
Breath sounds abnormal	65.69	19.55	36	14199	8971	56268861
Affective disorder	63.03	19.55	30	14205	5573	56272259
Chronic obstructive pulmonary disease	61.16	19.55	74	14161	57341	56220491
Nasal obstruction	59.14	19.55	19	14216	1232	56276600
Blood test abnormal	58.92	19.55	38	14197	12746	56265086
Granuloma	57.54	19.55	28	14207	5459	56272373
Eczema	55.81	19.55	49	14186	26104	56251728
Sleep apnoea syndrome	53.96	19.55	48	14187	26013	56251819
Paraesthesia oral	52.35	19.55	37	14198	14412	56263420
Weight decreased	50.12	19.55	154	14081	240560	56037272
Haemoptysis	49.28	19.55	46	14189	26514	56251318
Procedural pain	48.42	19.55	37	14198	16234	56261598
Polycystic ovaries	47.50	19.55	21	14214	3293	56274539
Respiratory disorder	46.74	19.55	50	14185	33907	56243925
Sarcoidosis	45.85	19.55	24	14211	5456	56272376
Lung hyperinflation	43.84	19.55	15	14220	1183	56276649
Death	43.54	19.55	16	14219	341410	55936422
Toxicity to various agents	42.27	19.55	4	14231	224560	56053272
Rhinitis allergic	41.06	19.55	26	14209	8448	56269384
Epilepsy	39.85	19.55	40	14195	25191	56252641
Lactose intolerance	38.51	19.55	17	14218	2655	56275177
Forced expiratory volume decreased	37.82	19.55	20	14215	4640	56273192
Eye pruritus	37.29	19.55	30	14205	14176	56263656
Dyslipidaemia	37.19	19.55	22	14213	6331	56271501
Sinusitis	37.06	19.55	122	14113	197459	56080373
Rheumatoid arthritis	36.76	19.55	26	14209	382578	55895254
Crystal arthropathy	35.38	19.55	9	14226	250	56277582
Alopecia	35.35	19.55	15	14220	293443	55984389
Drug ineffective	35.15	19.55	370	13865	918619	55359213
Systemic lupus erythematosus	34.44	19.55	3	14232	180075	56097757
Migraine	34.39	19.55	71	14164	86726	56191106
Ear pruritus	33.92	19.55	16	14219	2912	56274920
Herpes zoster	32.35	19.55	64	14171	75825	56202007
Arthropathy	31.92	19.55	6	14229	200269	56077563
Ligament pain	31.84	19.55	8	14227	211	56277621
Rales	30.83	19.55	24	14211	10816	56267016
Dyspepsia	30.42	19.55	66	14169	83405	56194427
Sneezing	28.96	19.55	27	14208	15533	56262299
Asthmatic crisis	28.32	19.55	12	14223	1698	56276134
Ankle fracture	27.74	19.55	27	14208	16376	56261456
Bronchitis	27.29	19.55	76	14159	112235	56165597
Seasonal allergy	26.79	19.55	27	14208	17081	56260751
Paraesthesia	26.64	19.55	83	14152	130431	56147401
Glossodynia	25.53	19.55	4	14231	152454	56125378
Blood pressure diastolic abnormal	25.28	19.55	22	14213	11576	56266256
Eosinophilia	24.91	19.55	28	14207	20049	56257783
Eosinophil count increased	24.55	19.55	20	14215	9617	56268215
Blood pressure systolic increased	23.18	19.55	39	14196	40797	56237035
Sinus pain	23.14	19.55	12	14223	2676	56275156
Pertussis	23.09	19.55	8	14227	655	56277177
Loss of personal independence in daily activities	22.73	19.55	58	14177	81311	56196521
Stent placement	22.65	19.55	13	14222	3538	56274294
Sinus tachycardia	22.38	19.55	28	14207	22416	56255416
Swelling face	22.35	19.55	46	14189	56023	56221809
Chondrocalcinosis pyrophosphate	21.84	19.55	9	14226	1188	56276644
Sensitivity to weather change	21.74	19.55	16	14219	6633	56271199
Contraindicated product administered	21.66	19.55	10	14225	186276	56091556
Restless legs syndrome	21.65	19.55	24	14211	16923	56260909
Joint swelling	21.48	19.55	25	14210	289775	55988057
Angioedema	21.45	19.55	38	14197	41415	56236417
Respiratory tract infection	21.21	19.55	35	14200	36036	56241796
Subclavian vein thrombosis	21.19	19.55	10	14225	1822	56276010
Abscess	20.38	19.55	22	14213	15059	56262773
Hepatic enzyme increased	20.23	19.55	9	14226	171375	56106457
Blood pressure systolic abnormal	20.21	19.55	18	14217	9759	56268073
Blood pressure diastolic increased	20.21	19.55	17	14218	8544	56269288
Radioallergosorbent test positive	20.14	19.55	4	14231	34	56277798
Allergy to animal	20.07	19.55	8	14227	969	56276863
Pulmonary function test decreased	19.89	19.55	12	14223	3579	56274253
Thrombocytopenia	19.83	19.55	5	14230	136219	56141613
Cardiac murmur	19.72	19.55	19	14216	11382	56266450
Stress	19.68	19.55	45	14190	58865	56218967

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Asthma	367.08	19.67	180	6646	42431	31648087
Wheezing	201.08	19.67	114	6712	35872	31654646
Appendicolith	103.98	19.67	41	6785	5690	31684828
Nasal polyps	85.04	19.67	27	6799	1986	31688532
Therapeutic product effect incomplete	84.21	19.67	72	6754	43624	31646894
Appendicitis	76.78	19.67	41	6785	11424	31679094
Sleep disorder due to a general medical condition	74.60	19.67	29	6797	3873	31686645
Nasal congestion	71.35	19.67	48	6778	20333	31670185
Obstructive airways disorder	67.58	19.67	39	6787	12625	31677893
Foetal malformation	66.09	19.67	13	6813	125	31690393
Stress	58.28	19.67	46	6780	24895	31665623
Rhinitis	57.59	19.67	26	6800	5038	31685480
Seasonal allergy	55.15	19.67	26	6800	5562	31684956
Ocular discomfort	54.53	19.67	19	6807	1864	31688654
Trisomy 18	53.15	19.67	13	6813	362	31690156
Cough	53.08	19.67	100	6726	134714	31555804
Cardiogenic shock	51.65	19.67	41	6785	22367	31668151
Full blood count abnormal	51.30	19.67	36	6790	16311	31674207
Sputum discoloured	50.39	19.67	26	6800	6750	31683768
Blood phosphorus increased	47.78	19.67	22	6804	4460	31686058
Eye pruritus	45.30	19.67	22	6804	5023	31685495
Middle insomnia	41.35	19.67	22	6804	6077	31684441
Glaucoma	40.42	19.67	22	6804	6358	31684160
Ventricular fibrillation	40.28	19.67	33	6793	18815	31671703
Nasal oedema	39.58	19.67	10	6816	319	31690199
Dyspnoea	39.55	19.67	162	6664	343317	31347201
Chest discomfort	38.16	19.67	50	6776	49319	31641199
Dermatitis allergic	36.08	19.67	20	6806	5989	31684529
Eczema	35.07	19.67	28	6798	15389	31675129
Anosmia	34.47	19.67	14	6812	2094	31688424
Loss of personal independence in daily activities	34.11	19.67	36	6790	28252	31662266
Lung diffusion disorder	33.38	19.67	7	6819	95	31690423
Forced expiratory volume decreased	32.95	19.67	15	6811	2962	31687556
Chronic obstructive pulmonary disease	32.22	19.67	44	6782	45122	31645396
SARS-CoV-2 sepsis	31.68	19.67	7	6819	123	31690395
Ocular hyperaemia	31.29	19.67	22	6804	9987	31680531
Abdominal distension	31.18	19.67	46	6780	50638	31639880
Central obesity	30.93	19.67	9	6817	492	31690026
Ascites	30.85	19.67	41	6785	40972	31649546
Productive cough	30.73	19.67	37	6789	33503	31657015
Pharyngeal paraesthesia	29.97	19.67	9	6817	549	31689969
Victim of child abuse	29.51	19.67	10	6816	902	31689616
Fungal disease carrier	26.81	19.67	7	6819	255	31690263
Nasal disorder	26.59	19.67	11	6815	1724	31688794
Inguinal hernia repair	26.44	19.67	7	6819	269	31690249
Polyp	25.30	19.67	13	6813	3343	31687175
Gastroenteritis eosinophilic	24.89	19.67	6	6820	157	31690361
Nasal septum deviation	24.81	19.67	9	6817	992	31689526
Conjunctivitis	24.76	19.67	18	6808	8605	31681913
Hyponatraemia	24.45	19.67	51	6775	73748	31616770
Laryngeal discomfort	23.64	19.67	6	6820	195	31690323
Alpha 2 globulin decreased	22.61	19.67	4	6822	20	31690498
Otosalpingitis	22.61	19.67	4	6822	20	31690498
Free androgen index decreased	22.45	19.67	4	6822	21	31690497
Sex hormone binding globulin decreased	22.45	19.67	4	6822	21	31690497
Androgen insensitivity syndrome	22.29	19.67	4	6822	22	31690496
Viral acanthoma	22.29	19.67	4	6822	22	31690496
Rhinorrhoea	22.09	19.67	26	6800	22986	31667532
Testicular microlithiasis	22.00	19.67	4	6822	24	31690494
Toxicity to various agents	21.92	19.67	6	6820	181481	31509037
Dehydroepiandrosterone decreased	21.86	19.67	4	6822	25	31690493
Urine calcium/creatinine ratio increased	21.86	19.67	4	6822	25	31690493
Eosinophilic pneumonia chronic	21.82	19.67	6	6820	267	31690251
Faecal calprotectin	21.59	19.67	4	6822	27	31690491
Bronchial obstruction	21.51	19.67	9	6817	1451	31689067
Rhinitis allergic	21.35	19.67	11	6815	2843	31687675
Cortisol decreased	21.26	19.67	8	6818	977	31689541
Sinusitis	20.70	19.67	32	6794	36664	31653854
Blue toe syndrome	20.41	19.67	5	6821	140	31690378
Blood test abnormal	20.37	19.67	14	6812	6127	31684391
Oropharyngeal candidiasis	20.18	19.67	7	6819	677	31689841

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Asthma	843.94	17.28	476	18415	120317	70789236
Wheezing	519.62	17.28	319	18572	93851	70815702
Obstructive airways disorder	381.04	17.28	170	18721	25943	70883610
Full blood count abnormal	278.36	17.28	149	18742	33729	70875824
Nasal congestion	264.87	17.28	183	18708	65489	70844064
Therapeutic product effect incomplete	208.92	17.28	205	18686	119677	70789876
Sleep disorder due to a general medical condition	161.71	17.28	71	18820	10405	70899148
Dyspnoea	154.82	17.28	502	18389	769558	70139995
Nasal polyps	148.91	17.28	53	18838	4463	70905090
Cough	148.05	17.28	290	18601	325087	70584466
Rhinitis	124.40	17.28	61	18830	11486	70898067
Chest discomfort	122.37	17.28	158	18733	124223	70785330
Productive cough	119.94	17.28	125	18766	78212	70831341
Gastrooesophageal reflux disease	119.89	17.28	134	18757	90705	70818848
Bronchial neoplasm	117.90	17.28	27	18864	449	70909104
Sputum discoloured	116.95	17.28	69	18822	18782	70890771
Nasal turbinate hypertrophy	116.32	17.28	28	18863	583	70908970
Throat clearing	108.80	17.28	33	18858	1678	70907875
Endometrial ablation	102.66	17.28	27	18864	813	70908740
Chronic sinusitis	101.18	17.28	48	18843	8403	70901150
Bronchiectasis	100.06	17.28	59	18832	16038	70893515
Blepharospasm	96.78	17.28	37	18854	3808	70905745
Bronchial haemorrhage	96.08	17.28	28	18863	1239	70908314
Rhonchi	94.98	17.28	36	18855	3619	70905934
Appendicolith	92.55	17.28	40	18851	5640	70903913
Blood immunoglobulin E increased	89.25	17.28	37	18854	4707	70904846
Rhinorrhoea	87.69	17.28	98	18793	66273	70843280
Malignant mediastinal neoplasm	82.86	17.28	23	18868	852	70908701
Eczema	80.66	17.28	69	18822	33712	70875841
Blood test abnormal	79.13	17.28	49	18842	14541	70895012
Bronchial disorder	79.02	17.28	28	18863	2326	70907227
Chronic obstructive pulmonary disease	76.88	17.28	99	18792	77542	70832011
Restrictive pulmonary disease	75.78	17.28	27	18864	2279	70907274
Hyper IgE syndrome	75.51	17.28	19	18872	478	70909075
Taste disorder	74.11	17.28	43	18848	11342	70898211
Toxicity to various agents	71.19	17.28	9	18882	382163	70527390
Stress	70.98	17.28	89	18802	67877	70841676
Total lung capacity increased	67.77	17.28	20	18871	925	70908628
Dust allergy	67.50	17.28	21	18870	1163	70908390
Eye pruritus	66.55	17.28	44	18847	14603	70894950
Respiratory tract inflammation	65.74	17.28	19	18872	816	70908737
Forced expiratory volume decreased	65.20	17.28	34	18857	7280	70902273
Affective disorder	64.49	17.28	34	18857	7445	70902108
Breath sounds abnormal	63.18	17.28	41	18850	13190	70896363
Secretion discharge	61.56	17.28	40	18851	12893	70896660
Macular degeneration	61.46	17.28	33	18858	7495	70902058
Sleep apnoea syndrome	56.96	17.28	56	18835	32657	70876896
Seasonal allergy	55.27	17.28	38	18853	13446	70896107
Paraesthesia oral	55.20	17.28	40	18851	15377	70894176
Sinusitis	55.13	17.28	132	18759	169063	70740490
Respiratory disorder	53.78	17.28	59	18832	39064	70870489
Nasal obstruction	53.62	17.28	19	18872	1578	70907975
Dyspnoea exertional	52.50	17.28	83	18808	78347	70831206
Appendicitis	52.27	17.28	40	18851	16693	70892860
Granuloma	49.91	17.28	29	18862	7666	70901887
Rhinitis allergic	49.85	17.28	31	18860	9264	70900289
Polycystic ovaries	49.34	17.28	21	18870	2851	70906702
Asthma-chronic obstructive pulmonary disease overlap syndrome	46.48	17.28	17	18874	1547	70908006
Loss of personal independence in daily activities	45.05	17.28	81	18810	84829	70824724
Middle insomnia	44.79	17.28	34	18857	14019	70895534
Weight decreased	44.53	17.28	182	18709	310306	70599247
Migraine	43.66	17.28	73	18818	72165	70837388
Anosmia	41.53	17.28	22	18869	4861	70904692
Lung hyperinflation	41.31	17.28	16	18875	1705	70907848
Lactose intolerance	41.16	17.28	17	18874	2141	70907412
Procedural pain	39.38	17.28	35	18856	17974	70891579
Death	37.08	17.28	49	18842	510012	70399541
Anaemia	36.84	17.28	32	18859	403391	70506162
Bronchitis	36.59	17.28	90	18801	117153	70792400
Acute kidney injury	35.11	17.28	45	18846	474579	70434974
Blood phosphorus increased	34.85	17.28	22	18869	6748	70902805
Polyp	33.69	17.28	22	18869	7148	70902405
Blood pressure diastolic increased	33.07	17.28	27	18864	12364	70897189
Sarcoidosis	32.78	17.28	21	18870	6606	70902947
Ear pruritus	32.41	17.28	16	18875	3054	70906499
Thrombocytopenia	31.73	17.28	12	18879	239098	70670455
Herpes zoster	31.59	17.28	70	18821	85165	70824388
Epilepsy	31.59	17.28	45	18846	38739	70870814
Cardiac murmur	31.36	17.28	26	18865	12160	70897393
Haemoptysis	31.09	17.28	52	18839	51400	70858153
Lower respiratory tract infection	30.86	17.28	82	18809	111831	70797722
Nasal oedema	30.83	17.28	12	18879	1295	70908258
Swelling face	30.65	17.28	58	18833	63106	70846447
Ligament pain	30.16	17.28	8	18883	249	70909304
SARS-CoV-2 sepsis	30.04	17.28	7	18884	126	70909427
Ankle fracture	29.99	17.28	28	18863	15316	70894237
Dyslipidaemia	29.55	17.28	23	18868	9837	70899716
Eosinophilic pneumonia chronic	29.31	17.28	9	18882	477	70909076
Lung diffusion disorder	29.30	17.28	7	18884	141	70909412
Dehydration	28.93	17.28	12	18879	226130	70683423
Cardiogenic shock	27.92	17.28	41	18850	36266	70873287
Sneezing	27.63	17.28	28	18863	16923	70892630
Eosinophilia	27.42	17.28	43	18848	40276	70869277
Dyspepsia	27.38	17.28	68	18823	89009	70820544
Victim of child abuse	27.15	17.28	10	18881	928	70908625
Ocular discomfort	27.08	17.28	16	18875	4361	70905192
Cardiac arrest	26.90	17.28	5	18886	159829	70749724
Asthmatic crisis	26.60	17.28	12	18879	1872	70907681
Haemoglobin decreased	26.06	17.28	11	18880	205148	70704405
Paraesthesia	25.50	17.28	91	18800	145446	70764107
Treatment failure	25.38	17.28	4	18887	144138	70765415
Inguinal hernia repair	25.10	17.28	7	18884	264	70909289
Fungal disease carrier	24.16	17.28	7	18884	303	70909250
Blood pressure diastolic abnormal	24.16	17.28	25	18866	15479	70894074
Synovitis	24.13	17.28	3	18888	129225	70780328
Neutropenia	23.93	17.28	20	18871	257136	70652417
Atopy	23.86	17.28	7	18884	317	70909236
Sensitivity to weather change	23.78	17.28	18	18873	7387	70902166
Platelet count decreased	23.54	17.28	9	18882	178213	70731340
Eosinophilic granulomatosis with polyangiitis	23.23	17.28	13	18878	3200	70906353
Throat irritation	23.11	17.28	37	18854	35267	70874286
Oropharyngeal pain	23.02	17.28	67	18824	96243	70813310
Ventricular fibrillation	22.88	17.28	32	18859	27079	70882474
Eosinophil count increased	22.74	17.28	24	18867	15198	70894355
Blood pressure systolic increased	22.32	17.28	48	18843	57211	70852342
Rheumatoid arthritis	22.24	17.28	27	18864	291778	70617775
Ovarian cyst	22.08	17.28	21	18870	11751	70897802
Overdose	21.72	17.28	9	18882	169736	70739817
Gastrointestinal haemorrhage	21.67	17.28	5	18886	137403	70772150
Respiratory failure	21.50	17.28	9	18882	168726	70740827
Cardiac failure congestive	21.22	17.28	5	18886	135452	70774101
Crepitations	21.20	17.28	18	18873	8696	70900857
Gastroenteritis eosinophilic	21.17	17.28	6	18885	240	70909313
Pertussis	20.67	17.28	8	18883	851	70908702
Respiratory tract infection	20.65	17.28	39	18852	42359	70867194
Rales	20.41	17.28	24	18867	17111	70892442
Cortisol decreased	20.31	17.28	10	18881	1897	70907656
White blood cell count decreased	20.24	17.28	10	18881	170131	70739422
Nasal disorder	20.20	17.28	12	18879	3302	70906251
Febrile neutropenia	20.13	17.28	15	18876	204303	70705250
Sinus disorder	20.05	17.28	25	18866	18934	70890619
Radioallergosorbent test positive	20.04	17.28	4	18887	33	70909520
Joint swelling	19.75	17.28	23	18868	253188	70656365
Asthenia	19.47	17.28	60	18831	457606	70451947
Drug interaction	19.23	17.28	46	18845	381395	70528158
Ocular hyperaemia	19.20	17.28	28	18863	24611	70884942
Autism spectrum disorder	18.97	17.28	8	18883	1062	70908491
Central obesity	18.86	17.28	9	18882	1594	70907959
Pharyngeal paraesthesia	18.82	17.28	10	18881	2222	70907331
Diarrhoea	18.77	17.28	127	18764	783214	70126339
Sinus pain	18.42	17.28	11	18880	3058	70906495
Influenza	18.15	17.28	69	18822	113631	70795922
Malignant neoplasm progression	18.10	17.28	5	18886	121734	70787819
Eosinophilic bronchitis	18.09	17.28	6	18885	408	70909145
Hypotension	17.92	17.28	52	18839	404329	70505224
Septic shock	17.87	17.28	4	18887	112254	70797299
Illness	17.71	17.28	31	18860	31760	70877793
Lung neoplasm malignant	17.68	17.28	27	18864	24715	70884838
Restless legs syndrome	17.44	17.28	23	18868	18405	70891148

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	D07AC17	DERMATOLOGICALS CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS CORTICOSTEROIDS, PLAIN Corticosteroids, potent (group III)
ATC	R01AD08	RESPIRATORY SYSTEM NASAL PREPARATIONS DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE Corticosteroids
ATC	R01AD12	RESPIRATORY SYSTEM NASAL PREPARATIONS DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE Corticosteroids
ATC	R01AD58	RESPIRATORY SYSTEM NASAL PREPARATIONS DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE Corticosteroids
ATC	R03AK06	RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics
ATC	R03AK10	RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics
ATC	R03AK11	RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics
ATC	R03AL08	RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
ATC	R03BA05	RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS Glucocorticoids
ATC	R03BA09	RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS Glucocorticoids
FDA MoA	N0000175450	Corticosteroid Hormone Receptor Agonists
FDA EPC	N0000175576	Corticosteroid
CHEBI has role	CHEBI:49167	anti-asthmatic drugs
CHEBI has role	CHEBI:50857	anti-allergic drugs
MeSH PA	D018926	Anti-Allergic Agents
MeSH PA	D018927	Anti-Asthmatic Agents
MeSH PA	D000893	Anti-Inflammatory Agents
MeSH PA	D001993	Bronchodilator Agents
MeSH PA	D003879	Dermatologic Agents
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D019141	Respiratory System Agents
CHEBI has role	CHEBI:50266	Prodrugs

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Chronic obstructive lung disease	indication	13645005	DOID:3083
Allergic rhinitis	indication	61582004
Chronic bronchitis	indication	63480004	DOID:6132
Pulmonary emphysema	indication	87433001
Asthma	indication	195967001	DOID:2841
Chronic Non-Allergic Rhinitis	indication
Mycosis	contraindication	3218000	DOID:1564
Ocular hypertension	contraindication	4210003	DOID:9282
Epistaxis	contraindication	12441001
Measles	contraindication	14189004	DOID:8622
Disease caused by parasite	contraindication	17322007
Glaucoma	contraindication	23986001	DOID:1686
Viral disease	contraindication	34014006	DOID:934
Hypercortisolism	contraindication	47270006
Perforation of nasal septum	contraindication	80142000
Bacterial infectious disease	contraindication	87628006
Operation on nose	contraindication	88733004
Bilateral cataracts	contraindication	95722004
Pulmonary tuberculosis	contraindication	154283005	DOID:2957
Ophthalmic herpes simplex	contraindication	186542001
Varicella-zoster virus infection	contraindication	309465005
Adrenal cortical hypofunction	contraindication	386584007	DOID:10493
Exposure to varicella	contraindication	444453009
Nasal Candidiasis	contraindication
Nasal Trauma	contraindication
Nasal Septal Ulcers	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	11.49	acidic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
0.1MG/INH;EQ 0.025MG BASE/INH	BREO ELLIPTA	GLAXO GRP LTD	N204275	May 10, 2013	RX	POWDER	INHALATION	RE44874	March 23, 2023	FOR THE LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS
0.1MG/INH;EQ 0.025MG BASE/INH	BREO ELLIPTA	GLAXO GRP LTD	N204275	May 10, 2013	RX	POWDER	INHALATION	RE44874	March 23, 2023	INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER
0.2MG/INH;EQ 0.025MG BASE/INH	BREO ELLIPTA	GLAXO GRP LTD	N204275	April 30, 2015	RX	POWDER	INHALATION	RE44874	March 23, 2023	INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER
0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH	TRELEGY ELLIPTA	GLAXOSMITHKLINE	N209482	Sept. 18, 2017	RX	POWDER	INHALATION	RE44874	March 23, 2023	INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA
0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH	TRELEGY ELLIPTA	GLAXOSMITHKLINE	N209482	Sept. 18, 2017	RX	POWDER	INHALATION	RE44874	March 23, 2023	INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA; AND ASTHMA
0.2MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH	TRELEGY ELLIPTA	GLAXOSMITHKLINE	N209482	Sept. 9, 2020	RX	POWDER	INHALATION	RE44874	March 23, 2023	INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA; AND ASTHMA
0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH	TRELEGY ELLIPTA	GLAXOSMITHKLINE	N209482	Sept. 18, 2017	RX	POWDER	INHALATION	8309572	April 27, 2025	METHOD OF INHIBITING THE BINDING OF ACETYLCHOLINE TO AN ACETYLCHOLINE RECEPTOR IN THE RESPIRATORY TRACT OF A HUMAN, COMPRISING CONTACTING THE RECEPTOR WITH AN EFFECTIVE AMOUNT OF UMECLIDINIUM, VIA TOPICAL APPLICATION
0.2MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH	TRELEGY ELLIPTA	GLAXOSMITHKLINE	N209482	Sept. 9, 2020	RX	POWDER	INHALATION	8309572	April 27, 2025	METHOD OF INHIBITING THE BINDING OF ACETYLCHOLINE TO AN ACETYLCHOLINE RECEPTOR IN THE RESPIRATORY TRACT OF A HUMAN, COMPRISING CONTACTING THE RECEPTOR WITH AN EFFECTIVE AMOUNT OF UMECLIDINIUM, VIA TOPICAL APPLICATION
0.1MG/INH;EQ 0.025MG BASE/INH	BREO ELLIPTA	GLAXO GRP LTD	N204275	May 10, 2013	RX	POWDER	INHALATION	7439393	May 21, 2025	INDICATED FOR LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PTS WITH A HISTORY OF EXACERBATIONS
0.1MG/INH;EQ 0.025MG BASE/INH	BREO ELLIPTA	GLAXO GRP LTD	N204275	May 10, 2013	RX	POWDER	INHALATION	7439393	May 21, 2025	INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING BRONCHITIS AND/OR EMPHYSEMA
0.1MG/INH;EQ 0.025MG BASE/INH	BREO ELLIPTA	GLAXO GRP LTD	N204275	May 10, 2013	RX	POWDER	INHALATION	7439393	May 21, 2025	INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER
0.1MG/INH;EQ 0.025MG BASE/INH	BREO ELLIPTA	GLAXO GRP LTD	N204275	May 10, 2013	RX	POWDER	INHALATION	7439393	May 21, 2025	INDICATED FOR THE ONCE-DAILY TREATMENT OF ASTHMA IN PATIENTS 18 YEARS AND OLDER
0.2MG/INH;EQ 0.025MG BASE/INH	BREO ELLIPTA	GLAXO GRP LTD	N204275	April 30, 2015	RX	POWDER	INHALATION	7439393	May 21, 2025	INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING BRONCHITIS AND/OR EMPHYSEMA
0.2MG/INH;EQ 0.025MG BASE/INH	BREO ELLIPTA	GLAXO GRP LTD	N204275	April 30, 2015	RX	POWDER	INHALATION	7439393	May 21, 2025	INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER
0.2MG/INH;EQ 0.025MG BASE/INH	BREO ELLIPTA	GLAXO GRP LTD	N204275	April 30, 2015	RX	POWDER	INHALATION	7439393	May 21, 2025	INDICATED FOR THE ONCE-DAILY TREATMENT OF ASTHMA IN PATIENTS 18 YEARS AND OLDER
0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH	TRELEGY ELLIPTA	GLAXOSMITHKLINE	N209482	Sept. 18, 2017	RX	POWDER	INHALATION	7439393	May 21, 2025	INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA
0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH	TRELEGY ELLIPTA	GLAXOSMITHKLINE	N209482	Sept. 18, 2017	RX	POWDER	INHALATION	7439393	May 21, 2025	MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 18 YRS AND OLDER, OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA
0.2MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH	TRELEGY ELLIPTA	GLAXOSMITHKLINE	N209482	Sept. 9, 2020	RX	POWDER	INHALATION	7439393	May 21, 2025	MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 18 YRS AND OLDER, OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA
0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH	TRELEGY ELLIPTA	GLAXOSMITHKLINE	N209482	Sept. 18, 2017	RX	POWDER	INHALATION	8183257	July 27, 2025	METHOD OF INHIBITING THE BINDING OF ACETYLCHOLINE TO AN ACETYLCHOLINE RECEPTOR IN THE RESPIRATORY TRACT OF A HUMAN, COMPRISING CONTACTING THE RECEPTOR WITH AN EFFECTIVE AMOUNT OF UMECLIDINIUM, VIA INHALATION
0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH	TRELEGY ELLIPTA	GLAXOSMITHKLINE	N209482	Sept. 18, 2017	RX	POWDER	INHALATION	8183257	July 27, 2025	METHOD OF INHIBITING THE BINDING OF ACETYLCHOLINE TO AN ACETYLCHOLINE RECEPTOR IN THE RESPIRATORY TRACT OF A HUMAN, COMPRISING CONTACTING THE RECEPTOR WITH AN EFFECTIVE AMOUNT OF UMECLIDINIUM, VIA TOPICAL APPLICATION
0.2MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH	TRELEGY ELLIPTA	GLAXOSMITHKLINE	N209482	Sept. 9, 2020	RX	POWDER	INHALATION	8183257	July 27, 2025	METHOD OF INHIBITING THE BINDING OF ACETYLCHOLINE TO AN ACETYLCHOLINE RECEPTOR IN THE RESPIRATORY TRACT OF A HUMAN, COMPRISING CONTACTING THE RECEPTOR WITH AN EFFECTIVE AMOUNT OF UMECLIDINIUM, VIA TOPICAL APPLICATION
0.1MG/INH;EQ 0.025MG BASE/INH	BREO ELLIPTA	GLAXO GRP LTD	N204275	May 10, 2013	RX	POWDER	INHALATION	8511304	June 14, 2027	INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER
0.1MG/INH;EQ 0.025MG BASE/INH	BREO ELLIPTA	GLAXO GRP LTD	N204275	May 10, 2013	RX	POWDER	INHALATION	8511304	June 14, 2027	LONG-TERM, ONCE DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS
0.2MG/INH;EQ 0.025MG BASE/INH	BREO ELLIPTA	GLAXO GRP LTD	N204275	April 30, 2015	RX	POWDER	INHALATION	8511304	June 14, 2027	INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER
0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH	TRELEGY ELLIPTA	GLAXOSMITHKLINE	N209482	Sept. 18, 2017	RX	POWDER	INHALATION	8511304	June 14, 2027	METHOD OF DISPENSING A COMBINATION MEDICAMENT PRODUCT FROM CLAIMED DELIVERY DEVICE, FOR EXAMPLE FOR THE TREATMENT OF ASTHMA OR COPD
0.2MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH	TRELEGY ELLIPTA	GLAXOSMITHKLINE	N209482	Sept. 9, 2020	RX	POWDER	INHALATION	8511304	June 14, 2027	METHOD OF DISPENSING A COMBINATION MEDICAMENT PRODUCT FROM CLAIMED DELIVERY DEVICE, FOR EXAMPLE FOR THE TREATMENT OF ASTHMA OR COPD
0.1MG/INH;EQ 0.025MG BASE/INH	BREO ELLIPTA	GLAXO GRP LTD	N204275	May 10, 2013	RX	POWDER	INHALATION	11116721	Feb. 26, 2029	INDICATED FOR LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PTS WITH A HISTORY OF EXACERBATIONS
0.1MG/INH;EQ 0.025MG BASE/INH	BREO ELLIPTA	GLAXO GRP LTD	N204275	May 10, 2013	RX	POWDER	INHALATION	11116721	Feb. 26, 2029	INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER
0.2MG/INH;EQ 0.025MG BASE/INH	BREO ELLIPTA	GLAXO GRP LTD	N204275	April 30, 2015	RX	POWDER	INHALATION	11116721	Feb. 26, 2029	INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER
0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH	TRELEGY ELLIPTA	GLAXOSMITHKLINE	N209482	Sept. 18, 2017	RX	POWDER	INHALATION	11090294	Nov. 29, 2030	MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) COMPRISING THE ONCE PER DAY ADMINISTRATION OF TRELEGY ELLIPTA, 100 MCG FLUTICASONE FUROATE/62.5 MCG UMECLIDINIUM/25 MCG VILANTEROL

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH	TRELEGY ELLIPTA	GLAXOSMITHKLINE	N209482	Sept. 18, 2017	RX	POWDER	INHALATION	Sept. 9, 2023	MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS AGED 18 YEARS AND OLDER
0.2MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH	TRELEGY ELLIPTA	GLAXOSMITHKLINE	N209482	Sept. 9, 2020	RX	POWDER	INHALATION	Sept. 9, 2023	NEW STRENGTH

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Glucocorticoid receptor	Nuclear hormone receptor	P04150	GCR_HUMAN	AGONIST	IC50	10.12	CHEMBL	CHEMBL
Mineralocorticoid receptor	Nuclear hormone receptor	P08235	MCR_HUMAN		IC50	6.83	CHEMBL
Progesterone receptor	Nuclear hormone receptor	P06401	PRGR_HUMAN		IC50	7.68	CHEMBL
Androgen receptor	Transcription factor		ANDR_RAT		IC50	5.73	CHEMBL
Glucocorticoid receptor	Transcription factor		GCR_RAT		IC50	8.30	CHEMBL

External reference:

ID	Source
D06315	KEGG_DRUG
4026165	VUID
N0000179800	NUI
4020529	VANDF
4026165	VANDF
CHEBI:74899	CHEBI
CHEBI:5134	CHEBI
GW6	PDB_CHEM_ID
CHEMBL1676	ChEMBL_ID
C523187	MESH_SUPPLEMENTAL_RECORD_UI
10892	IUPHAR_LIGAND_ID
6699	IUPHAR_LIGAND_ID
8521	INN_ID
DB08906	DRUGBANK_ID
JS86977WNV	UNII
DB13867	DRUGBANK_ID
41126	RXNORM
109674	MMSL
23848	MMSL
51966	MMSL
d01296	MMSL
004952	NDDF
012173	NDDF
108632003	SNOMEDCT_US
397192001	SNOMEDCT_US
426409006	SNOMEDCT_US
C1948374	UMLSCUI
C0082607	UMLSCUI
CHEMBL1201396	ChEMBL_ID
9854489	PUBCHEM_CID
5636	INN_ID
90566-53-3	SECONDARY_CAS_RN
D000068298	MESH_DESCRIPTOR_UI
5311101	PUBCHEM_CID
CUT2W21N7U	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
FLONASE SENSIMISTALLERGY RELIEF	HUMAN OTC DRUG LABEL	1	0135-0615	SPRAY, METERED	27.50 ug	NASAL	NDA	16 sections
FLONASE SENSIMISTALLERGY RELIEF	HUMAN OTC DRUG LABEL	1	0135-0616	SPRAY, METERED	27.50 ug	NASAL	NDA	16 sections
Breo Ellipta	HUMAN PRESCRIPTION DRUG LABEL	2	0173-0859	POWDER	100 ug	RESPIRATORY (INHALATION)	NDA	26 sections
Breo Ellipta	HUMAN PRESCRIPTION DRUG LABEL	2	0173-0859	POWDER	100 ug	RESPIRATORY (INHALATION)	NDA	26 sections
Arnuity Ellipta	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0874	POWDER	100 ug	RESPIRATORY (INHALATION)	NDA	27 sections
Arnuity Ellipta	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0874	POWDER	100 ug	RESPIRATORY (INHALATION)	NDA	27 sections
Arnuity Ellipta	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0876	POWDER	200 ug	RESPIRATORY (INHALATION)	NDA	27 sections
Arnuity Ellipta	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0876	POWDER	200 ug	RESPIRATORY (INHALATION)	NDA	27 sections
Breo Ellipta	HUMAN PRESCRIPTION DRUG LABEL	2	0173-0882	POWDER	200 ug	RESPIRATORY (INHALATION)	NDA	26 sections
Breo Ellipta	HUMAN PRESCRIPTION DRUG LABEL	2	0173-0882	POWDER	200 ug	RESPIRATORY (INHALATION)	NDA	26 sections
Trelegy Ellipta	HUMAN PRESCRIPTION DRUG LABEL	3	0173-0887	POWDER	100 ug	RESPIRATORY (INHALATION)	NDA	27 sections
Trelegy Ellipta	HUMAN PRESCRIPTION DRUG LABEL	3	0173-0887	POWDER	100 ug	RESPIRATORY (INHALATION)	NDA	27 sections
Arnuity Ellipta	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0888	POWDER	50 ug	RESPIRATORY (INHALATION)	NDA	27 sections
Arnuity Ellipta	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0888	POWDER	50 ug	RESPIRATORY (INHALATION)	NDA	27 sections
Trelegy Ellipta	HUMAN PRESCRIPTION DRUG LABEL	3	0173-0893	POWDER	200 ug	RESPIRATORY (INHALATION)	NDA	27 sections
Trelegy Ellipta	HUMAN PRESCRIPTION DRUG LABEL	3	0173-0893	POWDER	200 ug	RESPIRATORY (INHALATION)	NDA	27 sections
FLONASE SENSIMISTALLERGY RELIEF	HUMAN OTC DRUG LABEL	1	50090-5967	SPRAY, METERED	27.50 ug	NASAL	NDA	17 sections
FLONASE SENSIMISTALLERGY RELIEF	HUMAN OTC DRUG LABEL	1	50090-6075	SPRAY, METERED	27.50 ug	NASAL	NDA	17 sections
Veramyst	HUMAN PRESCRIPTION DRUG LABEL	1	54868-6168	SPRAY, METERED	27.50 ug	NASAL	NDA	27 sections
Fluticasone Furoate and Vilanterol	HUMAN PRESCRIPTION DRUG LABEL	2	66993-135	POWDER	100 ug	RESPIRATORY (INHALATION)	NDA authorized generic	26 sections
Fluticasone Furoate and Vilanterol	HUMAN PRESCRIPTION DRUG LABEL	2	66993-136	POWDER	200 ug	RESPIRATORY (INHALATION)	NDA authorized generic	26 sections
Breo Ellipta	HUMAN PRESCRIPTION DRUG LABEL	2	70518-2028	POWDER	100 ug	RESPIRATORY (INHALATION)	NDA	27 sections
Breo Ellipta	HUMAN PRESCRIPTION DRUG LABEL	2	70518-2028	POWDER	100 ug	RESPIRATORY (INHALATION)	NDA	27 sections